Trial Profile
The Dose-escalation Study Followed by an Extension Phase Evaluating the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients With Anaplastic Lymphoma Kinase ALK /Receptor Tyrosine Kinase ROS1 Positive
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Iruplinalkib (Primary)
- Indications Lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 10 Jan 2018 New trial record